🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Haihe Biopharma clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Haihe Biopharma as lead sponsor. Synced 26 Sep 2026
5Current trials
4Recruiting now
3Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Haihe Biopharma is the lead sponsor of 5 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are CYH33, HH2853 and Glumetinib. The most-studied condition is C-Met Exon 14 Mutation.

ClinicalTrials.gov trials by status

  • Recruiting480%
  • Active, closed120%

Trials by phase

  • Phase 1/2480%
  • Phase 2120%
01

Clinical trials sponsored by Haihe Biopharma

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
NCT04270591 · C-Met Exon 14 Mutation
Phase 1/2 Recruiting 2019-07 USA, China
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737 · ClinicalTrials.gov ↗ · FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma
Drug: HH2853
Phase 1/2 Recruiting 2020-09 USA, China
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT06909877 · ClinicalTrials.gov ↗ · Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Drug: HH2853
Phase 1/2 Recruiting 2022-07 China
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
NCT06975618 · ClinicalTrials.gov ↗ · PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)
Drug: CYH33
Phase 1/2 Recruiting 2023-08 China
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922 · ClinicalTrials.gov ↗ · Ovarian Cancer, Recurrent Cancer
Drug: CYH33
Phase 2 Active, closed 2021-10 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Haihe Biopharma trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Haihe Biopharma trials

10 conditions
C-Met Exon 14 Mutation1FL Lymphoma1Epithelioid Sarcoma1Peripheral T Cell Lymphoma1Advanced Solid Tumor1Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)1PIK3CA-Related Overgrowth Spectrum (PROS)1PIK3CA-related Vascular Malformations (PRVM)1Ovarian Cancer1Recurrent Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China54
Clinical trials in USA22

A trial with sites in more than one country appears in each of those registers.

05

Questions about Haihe Biopharma trials

How many clinical trials does Haihe Biopharma sponsor?

Haihe Biopharma is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Haihe Biopharma trials recruiting?

Yes. 4 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Haihe Biopharma testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are CYH33 (2), HH2853 (2) and Glumetinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.